Furthermore, a literature review indicated that immune checkpoint inhibitors targeting CD40/CD40L, CD27/CD70, and ICOS/ICOSL have been tested in clinical trials for advanced CRC patients29. This evidence concerns the gene ICOSLG and colorectal carcinoma.